Mylan Insists Complex Generics Strategy Is Poised To Deliver
Executive Summary
With one high-profile approval in its pocket – a version of Teva's blockbuster Copaxone – Mylan's management believes its strategy of investing in complex generics and biosimilars will help the company navigate challenges in the US generic market.
You may also be interested in...
Amgen Invests In Deals, Share Buybacks And Manufacturing As Sales Dip
Amgen reported reduced revenue for 2017 and its 2018 guidance anticipates either flat sales or further decline, so the company is under increasing pressure to spend its $41.7bn in cash in ways that boost earnings, but $14.4bn already is committed to buying stock back from shareholders.
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
CEO Heather Bresch talked to Scrip about how she will navigate the company through what has become a rough period for the US generic drug market and validation on complex generics and biosimilars.
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
CEO Heather Bresch talked to Scrip about how she will navigate the company through what has become a rough period for the US generic drug market and validation on complex generics and biosimilars.